1. Protein Tyrosine Kinase/RTK
    Autophagy
  2. c-Kit
    Bcr-Abl
    PDGFR
    Autophagy

Imatinib Mesylate (Synonyms: CGP-57148B; STI-571)

Cat. No.: HY-50946 Purity: 99.90%
Data Sheet SDS Handling Instructions

Imatinib Mesylate is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kit wt kinase with IC50 of ~100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.

For research use only. We do not sell to patients.
Imatinib Mesylate Chemical Structure

Imatinib Mesylate Chemical Structure

CAS No. : 220127-57-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
100 mg $50 In-stock
200 mg $65 In-stock
500 mg $75 In-stock
1 g $110 In-stock
5 g $195 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Imatinib Mesylate:

    Imatinib Mesylate purchased from MCE. Usage Cited in: J Bioenerg Biomembr. 2012 Feb;44(1):155-61.

    Differences in sensitivity of PDR-mutants to 3-BP, Imatinib methanesulfonate, Daunorubicin and Rhodamine 6 G. Minimal medium (YNB) with sucrose.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Imatinib Mesylate is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kit wt kinase with IC50 of ~100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.

    IC50 & Target

    IC50: ~100 nM (c-Kit, Bcr-Abl, and PDGFR)[1]

    In Vitro

    Imatinib (STI571) Mesylate inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. The concentration that produces 50% inhibition for these effects is approximately 100 nM[1]. Imatinib (STI571) mesylate is very effective (in vitro IC50 of 25 nM) against the chronic myeloid leukemia-causing kinase Bcr-Abl. Imatinib also efficiently inhibits Kit (in vitro IC50, 410 nM) and PDGFR (in vitro IC50, 380 nM)[2]. Imatinib (STI571) mesylate is a multi-target inhibitor of v-Abl, c-Kit and inhibits Bcr/Abl, v-Abl, Tel/Abl, the native PDGFβ receptor, and c-Kit, but it does not inhibit Src family kinases, c-Fms, Flt3, the EGFR or multiple other tyrosine kinases. Imatinib inhibits tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case, but it has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2[3]. Imatinib mesylate selectively inhibits the activity of Bcr/Abl, c-Kit and PDGFR kinases. Imatinib mesylate reveals distinct and rapid antileukemic activity in chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL)[4].

    In Vivo

    Animals treated with Imatinib Mesylate show a decrease of mean body weight throughout the whole study. Body weight loss is noticeable in mice from groups that receive chemotherapy and the vitamin D analog combined treatment. The body weight decrease of mice treat with both combined Imatinib mesylate and PRI-2191 is the highest (15%) on Day 22 of the experiment, but after that day, mice start to recover[4]. In a rat Ischemia/reperfusion injury (IRI) model, Imatinib mesylate attenuates lung injury by an antipermeability and antiinflammatory effect. The delivery and function of Imatinib mesylate in the lung is also confirmed in this model[5].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT02177825 St. Justine's Hospital Plexiform Neurofibromas June 2014 Phase 2
    NCT01221376 Renato Melaragno|Hospital Santa Marcelina Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+) February 2011 Phase 2
    NCT00702689 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sclerotic Graft Versus Host Disease|Imatinib Mesylate December 15, 2008 Phase 2
    NCT01222013 Renato Melaragno|Hospital Santa Marcelina Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Phase 2
    NCT00787384 Northern Italy Leukemia Group Hypereosinophilic Syndrome|Chronic Eosinophilic Leukemia|Chronic Idiopathic Hypereosinophilia October 2004 Phase 2
    NCT01297777 Hospital Virgen de la Salud Systemic Mastocytosis January 2011 Phase 4
    NCT00171912 Novartis Pharmaceuticals|Novartis Hypereosinophilic Syndrome|Systemic Mastocytosis|Chronic Myelomonocytic Leukemia|Dermatofibrosarcoma September 2004 Phase 2
    NCT00424515 Dana-Farber Cancer Institute|Novartis Mucosal Melanoma|Acral/Lentiginous Melanoma|Chronically Sun Damaged Melanomas July 2006 Phase 2
    NCT02413736 Heikki Joensuu|Scandinavian Sarcoma Group|Helsinki University Central Hospital Sarcoma May 2015 Phase 3
    NCT01151852 Asan Medical Center Gastrointestinal Stromal Tumors June 2010 Phase 3
    NCT00124748 Novartis Pharmaceuticals|Novartis Leukemia, Myeloid, Chronic Phase June 2005 Phase 3
    NCT02146846 Kerman University of Medical Sciences Chronic Myelogenous Leukemia October 2012
    NCT02462538 Arbeitsgemeinschaft medikamentoese Tumortherapie ALK+ Anaplastic Large Cell Lymphoma May 2015 Phase 1|Phase 2
    NCT01294202 Astex Pharmaceuticals Gastrointestinal Stromal Tumor (GIST) March 2011 Phase 2
    NCT00038675 M.D. Anderson Cancer Center|Novartis Pharmaceuticals Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Polycythemia Vera|Hypereosinophilic Syndrome|Mastocytosis June 2001
    NCT00115739 University of Michigan Cancer Center Thyroid Cancer February 2004 Phase 2
    NCT01781975 University of California, San Francisco|Juvenile Diabetes Research Foundation Diabetes Mellitus, Type I|Diabetes Mellitus, Insulin-Dependent, 1|Type 1 Diabetes Mellitus|Insulin-Dependent Diabetes Mellitus 1|IDDM January 2014 Phase 2
    NCT02260505 Centre Leon Berard Gastrointestinal Stromal Tumors|Resected Gastrointestinal Stromal Tumors|Non-metastatic|High Risk of Recurrence|KIT Gene Mutation December 2014 Phase 3
    NCT00858806 Università degli Studi di Brescia Chronic Myeloid Leukemia April 2008 Phase 2
    NCT00090987 AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation Sarcoma June 2005 Phase 2
    NCT00243191 Sarcoma Alliance for Research through Collaboration Dermatofibrosarcoma Protuberans May 2006 Phase 2
    NCT02363361 Professor Mikael Svensson, MD PhD|Karolinska University Hospital Cervical Spinal Cord Injury March 2015 Phase 2
    NCT00902174 Novartis Pharmaceuticals|Novartis Pulmonary Arterial Hypertension September 2009 Phase 3
    NCT00354523 M.D. Anderson Cancer Center|Novartis Pharmaceuticals Solid Tumor|Thyroid Cancer December 2004 Phase 1|Phase 2
    NCT01404715 University of California, San Francisco|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS) Healthy October 2011 Phase 1
    NCT00677092 Massachusetts General Hospital|Novartis Pharmaceuticals Nephrogenic Systemic Fibrosis December 2007 Phase 2
    NCT01795716 Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Chronic Myeloid Leukemia September 2012 Phase 1
    NCT00080665 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Breast Cancer December 2003 Phase 1
    NCT01097694 Brigham and Women's Hospital|Baim Institute for Clinical Research|National Heart, Lung, and Blood Institute (NHLBI) Asthma November 2010 Phase 2
    NCT00136409 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Novartis Myelofibrosis|Myeloid Metaplasia|Agnogenic Myeloid Metaplasia|Chronic Myelomonocytic Leukemia May 2002 Phase 2
    NCT02303899 Istituto Clinico Humanitas Mesothelioma, Malignant November 2014 Phase 2
    NCT00354913 Duke University|National Cancer Institute (NCI)|Novartis Pharmaceuticals Glioblastoma|Gliosarcoma May 2005 Phase 2
    NCT01738139 M.D. Anderson Cancer Center Advanced Cancers February 2013 Phase 1
    NCT00084630 National Cancer Institute (NCI) Adult Fibrosarcoma|Dermatofibrosarcoma Protuberans|Recurrent Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma May 2004 Phase 2
    NCT02685046 UMC Utrecht|Meander Medical Center|Erasmus Medical Center|Hubrecht Institute Colonic Neoplasms April 2016 Phase 2
    NCT00441155 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors November 2006 Phase 1
    NCT00237185 Novartis Pharmaceuticals|Novartis Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST) June 2000 Phase 2
    NCT01819389 Hospital Universitario Dr. Jose E. Gonzalez|Novartis Pharmaceuticals Leukemia, Myeloid, Chronic, BCR-ABL Positive October 2012 Phase 3
    NCT00278876 Asan Medical Center Sarcoma|Gastrointestinal Stromal Tumors April 2005 Phase 2
    NCT00154349 Novartis Pharmaceuticals|Novartis Philadelphia Chromosome Positive Acute Lymphocytic Leukemia October 2003 Phase 2
    NCT01275222 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors November 2002 Phase 1|Phase 2
    NCT00171860 Novartis Pharmaceuticals|Novartis Hypereosinophilic Syndrome September 2002 Phase 2
    NCT03193281 University of Auckland, New Zealand|Leukaemia & Blood Cancer New Zealand Chronic Myeloid Leukemia July 2017 Phase 2
    NCT01751919 Dong-A ST Co., Ltd. Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumor May 2012 Phase 1
    NCT00025246 National Cancer Institute (NCI) Gastrointestinal Stromal Tumor September 2001 Phase 2
    NCT00867113 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumor (GIST) July 22, 2009 Phase 2
    NCT00290771 Novartis Recurrent Glioblastoma Multiforme (GBM) February 2006 Phase 2
    NCT00171977 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors July 2004 Phase 4
    NCT01898377 Seoul National University Hospital Chronic Graft-versus-host Disease August 2013 Phase 2
    NCT00216112 Daniela Matei, MD|Novartis Pharmaceuticals|Sanofi|Walther Cancer Institute|Hoosier Cancer Research Network Ovarian Cancer December 2003 Phase 2
    NCT02317159 Cttq|Ruijin Hospital Chronic Myeloid Leukemia February 2015 Phase 4
    NCT01117987 Novartis Pharmaceuticals|Novartis Pulmonary Arterial Hypertension April 2010 Phase 3
    NCT00154336 Novartis Pharmaceuticals|Novartis Rheumatoid Arthritis July 2004 Phase 2
    NCT02461849 Samsung Medical Center Advanced, Refractory Cancer April 4, 2014 Phase 2
    NCT01545427 Lawson Health Research Institute|Novartis Pharmaceuticals Scleroderma April 2008 Phase 2
    NCT01011998 New Mexico Cancer Care Alliance Chronic Myelogenous Leukemia September 2009 Phase 2
    NCT02495519 Yonsei University Fibromatosis April 2014 Phase 2
    NCT00764595 Translational Research Informatics Center, Kobe, Hyogo, Japan|Niigata University Medical & Dental Hospital Gastrointestinal Stromal Tumor|Metastatic Cancer October 2008 Phase 2
    NCT02852486 University of Campinas, Brazil Leukemia, Chronic Myeloid June 2016 Phase 2
    NCT01400074 Seoul St. Mary's Hospital|Novartis Chronic Myeloid Leukemia January 2009 Phase 3
    NCT02614404 HuLow|Purdue University|University of Turin, Italy|Università degli Studi di Sassari|Hue University Plasmodium Falciparum Malaria November 2015 Phase 1|Phase 2
    NCT00510354 Novartis Pharmaceuticals|Novartis Progressive Gastrointestinal Stromal Tumor October 2006 Phase 4
    NCT01089595 Fox Chase Cancer Center|Novartis GIST|Metastatic Disease February 2009 Phase 2
    NCT00485485 M.D. Anderson Cancer Center|Novartis Head and Neck Cancer|Squamous Cell Cancer January 2007 Phase 2
    NCT00154375 Novartis Pharmaceuticals|Novartis Glioblastoma Multiforme|Astrocytoma October 2004 Phase 3
    NCT00338728 M.D. Anderson Cancer Center|Novartis Breast Cancer October 2003 Phase 2
    NCT00320190 Bristol-Myers Squibb Leukemia, Myeloid, Chronic August 2006 Phase 2
    NCT02130557 Avillion Development 1 Limited Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive June 2014 Phase 3
    NCT02268435 Asan Medical Center Gastrointestinal Stromal Tumors March 2015 Phase 1
    NCT00512902 University of California, Los Angeles|Novartis Pharmaceuticals Alveolitis|Systemic Sclerosis August 2007 Phase 1|Phase 2
    NCT00027586 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Melanoma|Skin Neoplasms September 2001 Phase 2
    NCT01460693 Newcastle University|Newcastle-upon-Tyne Hospitals NHS Trust|Bristol-Myers Squibb|Institute of Cancer Research, United Kingdom|Hammersmith Hospitals NHS Trust Myeloid Leukemia, Chronic, Chronic Phase August 2008 Phase 3
    NCT00852566 Norwegian University of Science and Technology Chronic Myeloid Leukemia March 2009 Phase 2
    NCT00615927 Duke University|Novartis Pharmaceuticals Glioblastoma|Gliosarcoma February 2006 Phase 2
    NCT00417807 Novartis Pharmaceuticals|Novartis Refractory Desmoplastic Small Round Cell Tumors August 2005 Phase 1|Phase 2
    NCT00506779 M.D. Anderson Cancer Center Uterine Cancer December 2003 Phase 1|Phase 2
    NCT00171158 Novartis Pharmaceuticals|Novartis Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis August 2004 Phase 2
    NCT03131999 Medical University of South Carolina|Columbia University Lymphangioleiomyomatosis June 1, 2017 Phase 1|Phase 2
    NCT00519090 Novartis Pharmaceuticals|Novartis Myelogenous Leukemia October 2007 Phase 3
    NCT00928642 Henry M. Jackson Foundation for the Advancement of Military Medicine|Novartis Ovarian Cancer|Primary Peritoneal Cancer June 2009 Phase 2
    NCT00420043 Novartis Healthy September 2006 Phase 1
    NCT01827930 Institut Bergonié Leukemia, Myeloid, Chronic-Phase July 2009 Phase 3
    NCT00039416 National Cancer Institute (NCI) Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis April 2002 Phase 2
    NCT01227356 Uppsala University|Uppsala University Hospital|Karolinska University Hospital Health Care Quality|Health Care Evaluation September 2004 Phase 2
    NCT00611689 SCRI Development Innovations, LLC|Novartis Refractory Malignancy|Solid Tumors July 2004 Phase 1
    NCT00026169 National Cancer Institute (NCI) Malignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific September 2001 Phase 1
    NCT00686218 City of Hope Medical Center|National Cancer Institute (NCI) Leukemia May 2008 Phase 1
    NCT00785785 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumor (GIST) March 2009 Phase 3
    NCT00041340 National Cancer Institute (NCI) Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer May 2002 Phase 2
    NCT00075400 National Cancer Institute (NCI) Recurrent Uterine Sarcoma|Uterine Carcinosarcoma January 2004 Phase 2
    NCT00041041 National Cancer Institute (NCI) Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer June 2002 Phase 2
    NCT00422825 Novartis Pharmaceuticals|Novartis Healthy June 2006 Phase 1
    NCT00632255 Imperial College London|Novartis Pharmaceuticals Chronic Myeloid Leukemia|Newly Diagnosed January 2008
    NCT00386373 M.D. Anderson Cancer Center Leukemia August 2003
    NCT00426179 Novartis Seasonal Allergic Rhinitis December 2006 Phase 1|Phase 2
    NCT00471497 Novartis Pharmaceuticals|Novartis Myelogenous Leukemia, Chronic July 31, 2007 Phase 3
    NCT01137916 Heidelberg University|Novartis Aggressive Fibromatosis|Desmoid Tumor June 2010 Phase 2
    NCT01541709 Asan Medical Center Gastrointestinal Stromal Tumors March 2012 Phase 2
    NCT00219726 Poitiers University Hospital|Novartis Chronic Myeloid Leukemia May 2002 Phase 2
    NCT01578213 University of Milano Bicocca Chronic Myeloid Leukemia November 2011 Phase 4
    NCT01011075 New Mexico Cancer Care Alliance|Fred Hutchinson Cancer Research Center|Novartis Non-small Cell Lung Cancer August 2009 Phase 2
    NCT01172548 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors August 2008 Phase 2
    NCT01083589 M.D. Anderson Cancer Center|Novartis Non-small Cell Lung Cancer January 2005 Phase 2
    NCT00116935 Scandinavian Sarcoma Group Sarcoma February 2004 Phase 3
    NCT00594555 University of Cincinnati|Novartis Chronic Myeloid Leukemia, Blast Crisis|Acute Myeloid Leukemia November 2007 Phase 2
    NCT00477269 Novartis Pharmaceuticals|Novartis Pulmonary Arterial Hypertension April 2006 Phase 2|Phase 3
    NCT00455559 AEterna Zentaris|M.D. Anderson Cancer Center Gastrointestinal Stromal Tumors August 2006 Phase 2
    NCT00193180 SCRI Development Innovations, LLC|Novartis|Aventis Pharmaceuticals Breast Cancer May 2005 Phase 2
    NCT01267695 Peking University Gastrointestinal Stromal Tumor May 2010 Phase 2
    NCT00684411 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Novartis T Cell Non-Hodgkin Lymphoma June 2008 Phase 2
    NCT00149136 Hospices Civils de Lyon Acute Lymphocytic Leukemia August 2002 Phase 2
    NCT00150072 Novartis Pharmaceuticals|Novartis Chordoma October 2004 Phase 2
    NCT00045188 National Cancer Institute (NCI) Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer August 2002 Phase 2
    NCT00331409 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Kidney Cancer January 2006 Phase 2
    NCT00928525 Italian Sarcoma Group Advanced Desmoid Tumor|Advanced Chondrosarcoma May 2007 Phase 2
    NCT01031628 Sarcoma Alliance for Research through Collaboration|Novartis Pharmaceuticals Gastrointestinal Stromal Tumors January 2010 Phase 3
    NCT00042952 National Cancer Institute (NCI) Ovarian Dysgerminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Ovarian Germ Cell Tumor|Stage II Malignant Testicular Germ Cell Tumor|Stage II Ovarian Germ Cell Tumor|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Testicular Seminoma June 2002 Phase 2
    NCT00237172 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors September 2002 Phase 2
    NCT00760877 Novartis Pharmaceuticals|Novartis CHRONIC MYELOGENOUS LEUKEMIA June 2009 Phase 3
    NCT00036751 National Cancer Institute (NCI) Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer April 2002 Phase 2
    NCT02257541 Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|M.D. Anderson Cancer Center|University of Pittsburgh Advanced Gastrointestinal Stromal Tumor (GIST) October 2, 2014 Phase 1|Phase 2
    NCT03228303 Assiut University Chronic Myeloid Leukemia August 1, 2017 Early Phase 1
    NCT01991379 Memorial Sloan Kettering Cancer Center|Array BioPharma|University of Pittsburgh Gastrointestinal Stromal Tumor (GIST) November 2013 Phase 1|Phase 2
    NCT00574873 Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer Chronic Myeloid Leukemia February 2008 Phase 3
    NCT00802841 Novartis Pharmaceuticals|Novartis Chronic Myelogenous Leukemia May 2009 Phase 3
    NCT01475110 Gruppo Italiano Malattie EMatologiche dell'Adulto Chronic Myeloid Leukaemia February 2012
    NCT00940563 Novartis Pharmaceuticals|Novartis Advanced Gastrointestinal Stromal Tumors March 2002 Phase 2
    NCT02431403 Pusan National University Hospital Lymphoma, Non-Hodgkin February 2015 Phase 1|Phase 2
    NCT01383447 National Cancer Institute (NCI) Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia October 2010 Phase 1|Phase 2
    NCT00402766 M.D. Anderson Cancer Center|Novartis Mesothelioma August 2006 Phase 1
    NCT00287105 Rennes University Hospital|Ministry of Health, France|Novartis Acute Lymphoblastic Leukemia|Philadelphia Chromosome December 2005 Phase 2
    NCT00390156 University of California, San Francisco|National Cancer Institute (NCI)|Novartis Unspecified Adult Solid Tumor August 2006 Phase 1
    NCT00030667 National Cancer Institute (NCI) Childhood Desmoplastic Small Round Cell Tumor|Childhood Synovial Sarcoma|Gastrointestinal Stromal Tumor|Lung Metastases|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Recurrent Osteosarcoma May 2002 Phase 2
    NCT00751036 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors June 2009 Phase 3
    NCT00021229 National Cancer Institute (NCI) Brain and Central Nervous System Tumors May 2001 Phase 1|Phase 2
    NCT00045734 National Cancer Institute (NCI) Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Grade III Meningioma|Adult Meningeal Hemangiopericytoma|Adult Meningioma|Recurrent Adult Brain Tumor February 2003 Phase 2
    NCT00049192 National Cancer Institute (NCI) Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Relapsing Chronic Myelogenous Leukemia November 2002 Phase 2
    NCT01593254 Bristol-Myers Squibb|ICON Clinical Research|PPD|Molecular MD|MultiPharma|Q2 solutions|Donald E. Morisky|MD Anderson Symptom Inventory (MDASI-CML)|OBiS, Inc|Steering Committee Chronic Phase Chronic Myeloid Leukemia October 29, 2012 Phase 2
    NCT02174445 Prof. Dr. Nikolas von Bubnoff|Novartis|University Hospital Freiburg Chronic Myeloid Leukemia March 2014 Phase 3
    NCT02272777 Novartis Pharmaceuticals|Novartis Leukemia July 17, 2014 Phase 3
    NCT00478985 University Hospital, Bordeaux Myeloid Leukemia, Chronic June 2007
    NCT01511289 Il-Yang Pharm. Co., Ltd. Leukemia|Leukemia, Myeloid|Leukemia, Myelogenous, Chronic, BCR-ABL Positive|Philadelphia Chromosome|Bone Marrow Diseases|Hematologic Diseases August 2011 Phase 3
    NCT00861471 New York University School of Medicine|Novartis Prostate Cancer|Prostatic Neoplasms May 2005 Phase 1|Phase 2
    NCT00555581 Hospital for Special Surgery, New York|Novartis Pharmaceuticals Systemic Sclerosis August 2007 Phase 2
    NCT00025415 National Cancer Institute (NCI) Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic August 2001 Phase 1
    NCT00479934 University Hospital, Bordeaux|Ministry of Health, France|Novartis Scleroderma, Localized|Scleroderma, Systemic December 2007 Phase 2
    NCT00387933 Duke University|National Cancer Institute (NCI) Brain and Central Nervous System Tumors July 2005 Phase 1
    NCT00237120 Novartis Chronic Myelogenous Leukemia in Chronic Phase November 2002 Phase 3
    NCT00091078 National Cancer Institute (NCI) Gastrointestinal Stromal Tumor September 2005 Phase 2
    NCT00154388 Novartis Pharmaceuticals|Novartis Life Threatening Diseases February 2001 Phase 2
    NCT01503502 Jiangsu HengRui Medicine Co., Ltd. Myelogenous Leukemia, Chronic August 2011 Phase 2
    NCT01483014 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors June 2008 Phase 2
    NCT01309997 Lee, Stephanie|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center Graft Versus Host Disease|Systemic Scleroderma March 2011 Phase 2
    NCT00500188 M.D. Anderson Cancer Center|Novartis Gastrointestinal Stromal Tumors July 2003 Phase 2
    NCT01216085 Novartis Pharmaceuticals|Novartis CML|Imatinib August 2010 Phase 2
    NCT00470470 National Cancer Institute (NCI) Acral Lentiginous Malignant Melanoma|Recurrent Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma|Stage IV Melanoma April 2007 Phase 2
    NCT02924714 Oslo University Hospital Gastrointestinal Stromal Tumor January 2017 Phase 2
    NCT00054431 National Cancer Institute (NCI) Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Relapsing Chronic Myelogenous Leukemia January 2003 Phase 2
    NCT00101088 National Cancer Institute (NCI) Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Relapsing Chronic Myelogenous Leukemia April 2005 Phase 1
    NCT00506831 Stanford University Scleroderma, Systemic July 2007 Phase 1|Phase 2
    NCT02480608 University of Leipzig Leukemia, Myelogenous, Chronic, BCR-ABL Positive April 2004 Phase 1|Phase 2
    NCT00087152 National Cancer Institute (NCI) Breast Cancer June 2004 Phase 2
    NCT00068380 National Cancer Institute (NCI) Recurrent Gastric Cancer|Stage IV Gastric Cancer March 2004 Phase 2
    NCT00314873 Indiana University School of Medicine|Indiana University Thymic Carcinoma April 2006 Phase 1
    NCT00585221 University of Utah|Schering-Plough Gastrointestinal Stromal Tumors|Cancer Brain|Solid Tumors July 2007 Phase 2
    NCT01782508 Beijing Cancer Hospital Melanoma August 2012 Phase 2
    NCT00030394 National Cancer Institute (NCI) Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia September 2002 Phase 2
    NCT00047502 M.D. Anderson Cancer Center Chronic Myelogenous Leukemia November 2002 Phase 1
    NCT00080678 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Metastatic Cancer|Prostate Cancer May 2003 Phase 2
    NCT00040105 M.D. Anderson Cancer Center|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Leukemia, Myeloid, Chronic October 2002 Phase 1
    NCT00372476 Novartis Pharmaceuticals|Novartis Breast Cancer June 2006 Phase 4
    NCT01281865 National Cancer Institute (NCI) Adult Synovial Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma January 2011 Phase 1|Phase 2
    NCT00333840 Novartis Pharmaceuticals|Novartis Chronic Myelogenous Leukemia June 2000 Phase 3
    NCT00499889 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Leukemia February 2003 Phase 2
    NCT00287846 UNICANCER Desmoid Tumor September 2004 Phase 1|Phase 2
    NCT01343173 University Hospital, Bordeaux Chronic Myeloid Leukaemia April 2011
    NCT00068783 National Cancer Institute (NCI) Recurrent Neuroendocrine Carcinoma of the Skin|Stage II Neuroendocrine Carcinoma of the Skin|Stage III Neuroendocrine Carcinoma of the Skin October 2003 Phase 2
    NCT00180921 Gustave Roussy, Cancer Campus, Grand Paris Cancer of the Head and Neck|Carcinoma, Adenoid Cystic July 2004 Phase 2
    NCT02896829 University Hospital, Bordeaux Chronic Myeloid Leukemia April 2013
    NCT01126814 University Health Network, Toronto Leukemia July 2004 Phase 1|Phase 2
    NCT00028002 National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|American College of Radiology Imaging Network Gastrointestinal Stromal Tumor February 2002 Phase 2
    NCT02687425 Meng Li|Tongji Hospital Leukemia, Myelogenous, Chronic, BCR-ABL Positive February 2016 Phase 2
    NCT00956072 European Organisation for Research and Treatment of Cancer - EORTC Gastrointestinal Stromal Tumor May 2009 Phase 3
    NCT00415909 M.D. Anderson Cancer Center|Abiogen Pharma Chronic Myelogenous Leukemia December 2006 Phase 2
    NCT00510653 M.D. Anderson Cancer Center Ovarian Cancer March 2002 Phase 2
    NCT01175109 Deric M Park MD|University of Virginia Chordoma October 2011 Phase 1
    NCT00427583 Novartis Pharmaceuticals|Novartis Malignant Peripheral Nerve Sheath Tumors May 2006 Phase 2|Phase 3
    NCT00707408 Nantes University Hospital AML February 2004 Phase 2
    NCT00981942 University of Aarhus Nephrogenic Systemic Fibrosis September 2009 Phase 3
    NCT00004932 Children's Oncology Group|National Cancer Institute (NCI) Leukemia January 2002 Phase 1
    NCT00171899 Novartis Pharmaceuticals|Novartis Chronic Myelogenous Leukemia April 2005 Phase 4
    NCT00601510 Technische Universität München Gastric Cancer November 2007 Phase 1
    NCT00428909 Novartis Pharmaceuticals|Novartis Chronic Myeloid Leukemia (CML) November 2006 Phase 1
    NCT01564836 Seoul St. Mary's Hospital|Ministry of Health & Welfare, Korea Chronic Myeloid Leukemia|Imatinib|Complete Molecular Response June 2010
    NCT00573326 Azienda Ospedaliera Universitaria Policlinico|Università Politecnica delle Marche Systemic Sclerosis February 2009 Phase 2
    NCT00268229 The Cleveland Clinic|National Cancer Institute (NCI) Leukemia July 2003 Phase 1
    NCT02709083 Emory University Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia October 2016 Phase 2
    NCT00052949 National Cancer Institute (NCI)|Cancer and Leukemia Group B Recurrent Small Cell Lung Cancer May 2003 Phase 2
    NCT01860456 University of Pisa Chronic Myeloid Leukemia May 2013
    NCT01568645 National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Pulmonary Hypertension March 2, 2012 Phase 1
    NCT00245128 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Chronic Myeloproliferative Disorders August 2005 Phase 2
    NCT00732784 Jan Beumer|Novartis Pharmaceuticals|University of Pittsburgh Healthy November 2008 Phase 1
    NCT00183833 University of Southern California|Novartis Colon Cancer|Colorectal Cancer December 2002 Phase 1
    NCT00084825 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Metastatic Cancer|Prostate Cancer May 2003 Phase 2
    NCT02812693 Joanne Jeter|National Cancer Institute (NCI)|Merck Ltd.|Ohio State University Comprehensive Cancer Center Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma November 2016 Phase 1|Phase 2
    NCT00430066 Niguarda Hospital Polycythemia Vera February 2007 Phase 2
    NCT00171223 Novartis Pharmaceuticals|Novartis Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia August 2004 Phase 2
    NCT00171249 Novartis Pharmaceuticals|Novartis Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia August 2004 Phase 2
    NCT00219752 Poitiers University Hospital|Novartis Chronic Myeloid Leukemia May 2002 Phase 2
    NCT00193258 SCRI Development Innovations, LLC|Genentech, Inc.|Novartis Clear Cell Renal Cell Carcinoma June 2004 Phase 1|Phase 2
    NCT00041197 National Cancer Institute (NCI) Gastrointestinal Stromal Tumor June 2002 Phase 3
    NCT00891527 Boston Children’s Hospital Pulmonary Veno Occlusive Disease October 2008 Phase 1|Phase 2
    NCT00038610 M.D. Anderson Cancer Center|Novartis Pharmaceuticals Leukemia March 2001 Phase 2
    NCT00324077 Bristol-Myers Squibb Myeloid Leukemia, Chronic, Chronic-Phase August 2006 Phase 1
    NCT00408460 University of Washington|National Cancer Institute (NCI) Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer February 2006 Phase 2
    NCT00854841 Pusan National University Hospital Chronic Myeloid Leukemia
    NCT00446004 University of Pittsburgh|Novartis Healthy April 2007 Phase 1
    NCT02644525 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) Loaisis December 21, 2015 Phase 2
    NCT00088231 M.D. Anderson Cancer Center|Novartis Acute Myelogenous Leukemia|Agnogenic Myeloid Metaplasia|Chronic Myelogenous Leukemia July 2004 Phase 1|Phase 2
    NCT00500110 M.D. Anderson Cancer Center|Novartis Pharmaceuticals Prostate Cancer June 2003 Phase 2
    NCT00122473 Dermatologic Cooperative Oncology Group Dermatofibrosarcoma January 2004 Phase 1|Phase 2
    NCT00015847 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Leukemia April 2001 Phase 2
    NCT00015834 National Cancer Institute (NCI) Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Relapsing Chronic Myelogenous Leukemia May 2001 Phase 1|Phase 2
    NCT00403156 Vitreous -Retina- Macula Consultants of New York|Genentech, Inc. Choroidal Neovascularization November 2006 Phase 1
    NCT02712112 Asan Medical Center Gastrointestinal Stromal Tumors (GISTs) January 2016 Phase 2
    NCT01392495 Novartis Pharmaceuticals|Novartis Pulmonary Arterial Hypertension June 2011 Phase 3
    NCT00481247 Bristol-Myers Squibb Myeloid Leukemia, Chronic September 2007 Phase 3
    NCT00281996 Northwestern University|National Cancer Institute (NCI) Pancreatic Cancer March 2005 Phase 1
    NCT02204644 Jiangsu Hansoh Pharmaceutical Co., Ltd. CML, CML-CP,MMR,TKI June 2014 Phase 3
    NCT00812240 AB Science Gastrointestinal Stromal Tumors January 2009 Phase 3
    NCT00867334 Inova Health Care Services|Novartis Pharmaceuticals Colorectal Neoplasm|Colorectal Cancer June 2009 Phase 1|Phase 2
    NCT02129166 University of Florida Healthy Volunteers September 2014 Phase 1
    NCT00022490 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Leukemia June 2001 Phase 2
    NCT00327262 Central European Leukemia Study Group Chronic Myeloid Leukemia January 2004 Phase 3
    NCT00070499 National Cancer Institute (NCI) Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase of Disease August 15, 2004 Phase 2
    NCT01275196 Novartis Pharmaceuticals|Novartis Chronic Myeloid Leukemia April 2011 Phase 3
    NCT00009906 National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|NCIC Clinical Trials Group Gastrointestinal Stromal Tumor December 2000 Phase 3
    NCT00881049 Peking University|Novartis Metastatic Melanoma December 2008 Phase 2
    NCT01926548 CJ HealthCare Corporation Healthy February 2012 Phase 1
    NCT00093639 Novartis Pharmaceuticals|Novartis Leukemia August 2004 Phase 1|Phase 2
    NCT00114959 ChemGenex Pharmaceuticals|Teva Pharmaceutical Industries Myeloid Leukemia, Chronic|Myeloid Leukemia, Chronic, Accelerated-Phase|Blast Phase|Myeloid Leukemia, Chronic, Chronic-Phase October 2005 Phase 2
    NCT00161213 University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Pancreatic Cancer September 2005 Phase 2
    NCT00049127 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Adult Anaplastic Oligodendroglioma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm June 2003 Phase 1|Phase 2
    NCT00685828 European Organisation for Research and Treatment of Cancer - EORTC|Italian Sarcoma Group|Australasian Gastro-Intestinal Trials Group|Scandinavian Sarcoma Group Gastrointestinal Stromal Tumor January 2001 Phase 3
    NCT00079313 National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Chronic Myelomonocytic Leukemia|Chronic Myelogenous Leukemia January 14, 2004 Phase 2
    NCT00323362 Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Novartis Lung Cancer April 2006 Phase 2
    NCT02891395 University Hospital, Lille|Novartis Graft Versus Host Disease December 2012 Phase 2
    NCT00324987 National Cancer Institute (NCI) Gastrointestinal Stromal Tumor April 2008 Phase 3
    NCT00171938 Novartis Glioblastoma April 2004 Phase 2
    NCT00573404 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Gastrointestinal Stromal Tumor July 2007 Phase 1
    NCT00084513 Fox Chase Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific August 2004 Phase 1
    NCT00421317 Centre Oscar Lambret|Novartis|National Cancer Institute, France Melanoma December 2005 Phase 2
    NCT00402662 Yale University|Novartis Metastatic Melanoma February 2006 Phase 2
    NCT02977312 Hikma Pharmaceuticals LLC Chronic Myeloid Leukemia, Chronic Phase August 2012
    NCT00784446 University of Cologne|Roche Pharma AG|Novartis|Sanofi Stage IV Colorectal Cancer April 2008 Phase 1|Phase 2
    NCT00763763 Assistance Publique - Hôpitaux de Paris Leukemia, Lymphocytic, Acute|Philadelphia Chromosome|Blast Crisis|Leukemia, Myeloid, Chronic December 2004 Phase 2
    NCT00045669 University Health Network, Toronto|National Cancer Institute (NCI) Head and Neck Cancer July 2002 Phase 2
    NCT02365441 Australasian Gastro-Intestinal Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Scandinavian Sarcoma Group Gastrointestinal Stromal Tumour February 2015 Phase 2
    NCT00146913 Hospices Civils de Lyon Chronic Myeloid Leukemia March 2004 Phase 2
    NCT00760981 Stanford University|Novartis Graft vs Host Disease September 2008 Phase 1
    NCT00219765 Poitiers University Hospital|Ministry of Health, France|Novartis Chronic Myeloid Leukemia May 2001 Phase 1|Phase 2
    NCT00038194 M.D. Anderson Cancer Center|Novartis Prostate Cancer October 2001 Phase 1
    NCT00210119 Institut Bergonié|Novartis Myeloid Leukemia, Chronic September 2005 Phase 2
    NCT00904735 Istituto Scientifico H. San Raffaele|National Cancer Institute (NCI) Brain and Central Nervous System Tumors June 2009 Phase 2
    NCT00401024 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Brain and Central Nervous System Tumors July 2006
    NCT02421926 Asan Medical Center Leukemia, Myelogenous, Chronic, BCR-ABL Positive October 2014
    NCT00509093 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Leukemia December 2008 Phase 2
    NCT01188889 University of Michigan Cancer Center|Novartis Chronic Myeloid Leukemia September 2013 Phase 1|Phase 2
    NCT00039585 National Cancer Institute (NCI) Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer May 2002 Phase 2
    NCT02576080 Assistance Publique Hopitaux De Marseille Gastrointestinal Stromal Tumor October 2015 Phase 3
    NCT00323063 Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Novartis Pharmaceuticals|Rutgers Cancer Institute of New Jersey Breast Cancer May 1, 2006 Phase 2
    NCT00551252 Gruppo Italiano MEsotelioma Mesothelioma January 2008 Phase 2
    NCT00510926 University of Bologna Myeloid Leukemia, Chronic, Chronic-Phase January 2004 Phase 2
    NCT02103322 Amneal Pharmaceuticals, LLC|Accutest Research Laboratories (I) Pvt. Ltd. Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumor February 2014 Phase 2|Phase 3
    NCT01048320 Royal Marsden NHS Foundation Trust Advanced Pancreatic Cancer July 2006 Phase 1
    NCT00074308 National Cancer Institute (NCI) Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma|Unspecified Adult Solid Tumor, Protocol Specific October 2003 Phase 1|Phase 2
    NCT00039364 European Organisation for Research and Treatment of Cancer - EORTC Brain and Central Nervous System Tumors March 2002 Phase 2
    NCT01188278 Bristol-Myers Squibb Leukemia, Myeloid, Chronic-Phase (CML-CP) July 2010
    NCT00010049 North American Brain Tumor Consortium|National Cancer Institute (NCI) Brain and Central Nervous System Tumors November 2002 Phase 1|Phase 2
    NCT00062205 City of Hope Medical Center|National Cancer Institute (NCI) Sarcoma June 2002 Phase 2
    NCT00031915 National Cancer Institute (NCI) Childhood Malignant Fibrous Histiocytoma of Bone|Sarcoma June 2002 Phase 2
    NCT00372567 Pfizer Gastrointestinal Stromal Tumor June 2007 Phase 3
    NCT00244829 Fred Hutchinson Cancer Research Center Leukemia January 2004 Phase 1|Phase 2
    NCT00103168 European Organisation for Research and Treatment of Cancer - EORTC|Italian Sarcoma Group|UNICANCER|Grupo Espanol de Investigacion en Sarcomas Gastrointestinal Stromal Tumor December 2004 Phase 3
    NCT00066326 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Leukemia June 2003 Phase 1
    NCT00085475 European Organisation for Research and Treatment of Cancer - EORTC Sarcoma April 2004 Phase 2
    NCT00845221 Poitiers University Hospital Chronic Myeloid Leukemia July 2004 Phase 4
    NCT01046487 Centre Oscar Lambret Cancer January 2009 Phase 1
    NCT00253565 Herbert Hurwitz|National Cancer Institute (NCI)|Duke University Unspecified Adult Solid Tumor, Protocol Specific August 2003 Phase 1
    NCT00064285 Virginia Commonwealth University|National Cancer Institute (NCI) Leukemia June 2003 Phase 1
    NCT03007147 Children's Oncology Group|National Cancer Institute (NCI) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia July 2017 Phase 3
    NCT00301093 Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Beth Israel Deaconess Medical Center Leukemia September 2005 Phase 1
    NCT01804985 University of Liverpool|Newcastle University|Imperial College London|University of Glasgow Chronic Myeloid Leukaemia December 2013 Phase 2
    NCT00425646 University of Washington|National Cancer Institute (NCI) Lung Cancer November 2006 Phase 2
    NCT00718263 Novartis Pharmaceuticals|Novartis Myelogenous Leukemia, Chronic April 2008 Phase 3
    NCT00131274 Daniels, Craig E., M.D.|Novartis Idiopathic Pulmonary Fibrosis|Lung Disease|Pulmonary Fibrosis April 2003 Phase 2|Phase 3
    NCT00483366 University of Nebraska|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific August 2006 Phase 1
    NCT00376467 Gruppo Italiano Malattie EMatologiche dell'Adulto Acute Lymphoblastic Leukemia December 2001 Phase 2
    NCT00514969 University of Bologna Chronic Myeloid Leukemia August 2000 Phase 2
    NCT00103844 Bristol-Myers Squibb Chronic Myeloid Leukemia|Philadelphia-Positive Myeloid Leukemia February 2005 Phase 2
    NCT00471328 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors March 2007 Phase 3
    NCT00219739 Poitiers University Hospital|Ministry of Health, France|Novartis|Roche Pharma AG Chronic Myeloid Leukemia September 2003 Phase 3
    NCT00112775 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Leukemia March 2005 Phase 2
    NCT00081133 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Leukemia December 2003 Phase 1|Phase 2
    NCT00112632 Technische Universität München Gastrointestinal Stromal Tumor February 2005 Phase 2
    NCT00290485 Maisonneuve-Rosemont Hospital|Hippocrate Research & Development Gastrointestinal Stromal Tumors August 2005 Phase 2
    NCT00362466 Bristol-Myers Squibb Leukemia April 2007 Phase 3
    NCT01025505 Gruppo Italiano Malattie EMatologiche dell'Adulto Treatment|Stem Cell Transplantation June 2012 Phase 2
    NCT00052494 University Health Network, Toronto|National Cancer Institute (NCI) Lung Cancer April 2003 Phase 1
    NCT00039377 National Cancer Institute (NCI) Adult Acute Lymphoblastic Leukemia in Remission April 2002 Phase 2
    NCT00028847 Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) Leukemia April 2001 Phase 1|Phase 2
    NCT00354068 Duke University|National Cancer Institute (NCI) Brain and Central Nervous System Tumors July 2004 Phase 1
    NCT00045604 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Lung Cancer July 2002 Phase 1
    NCT00702403 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Philadelphia Positive Adult Acute Lymphoblastic Leukemia|Philadelphia Positive Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childho April 2008 Phase 1|Phase 2
    NCT00053248 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Leukemia October 2002 Phase 1|Phase 2
    NCT00006357 European Organisation for Research and Treatment of Cancer - EORTC Endometrial Cancer|Gastrointestinal Stromal Tumor|Ovarian Cancer|Sarcoma|Small Intestine Cancer August 2000 Phase 1|Phase 2
    NCT00006475 Novartis Leukemia September 2000 Phase 2
    NCT00006052 Novartis Leukemia June 2000 Phase 2
    NCT00045422 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Leukemia April 2002 Phase 2
    NCT00297570 Sheba Medical Center Leukemia, Myeloid, Philadelphia-Positive February 2006 Phase 3
    NCT02204722 Dong-A ST Co., Ltd.|SeoulCRO Chronic Myeloid Leukemia September 2014 Phase 4
    NCT00618501 Asan Medical Center|National Cancer Institute (NCI) Leukemia October 2005 Phase 2
    NCT00006053 Novartis Leukemia June 2000 Phase 2
    NCT01491763 PETHEMA Foundation Acute Lymphoblastic Leukemia Ph Positive January 2008 Phase 4
    NCT00258271 University of Rochester Leukemia March 2005 Phase 1
    NCT00130195 Japan Adult Leukemia Study Group Acute Lymphoblastic Leukemia September 2002 Phase 2
    NCT01392469 Novartis Pharmaceuticals|Novartis Pulmonary Arterial Hypertension April 20, 2011 Phase 3
    NCT00199186 Johann Wolfgang Goethe University Hospital Philadelphia Positive Acute Lymphoblastic Leukemia|Lymphoid Blastic Phase of Chronic Myeloid Leukemia March 2002 Phase 2
    NCT00323791 University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Kidney Cancer April 2006 Phase 2
    NCT01650805 Ariad Pharmaceuticals Chronic Myeloid Leukemia June 2012 Phase 3
    NCT01227135 Lynn McMahon|Medical Research Council|CRUK Trials unit Glasgow|University of Glasgow Leukemia March 2010 Phase 2
    NCT02602314 Gruppo Italiano Malattie EMatologiche dell'Adulto Chronyc Myeloid Leukemia December 2016 Phase 4
    NCT01003054 M.D. Anderson Cancer Center Chronic Myelogenous Leukemia March 2005 Phase 2
    NCT00982488 Bristol-Myers Squibb Leukemia October 2007 Phase 2
    NCT02001818 Australasian Leukaemia and Lymphoma Group|Merck Sharp & Dohme (Australia) Pty Limited|Novartis Pharmaceuticals Chronic Myeloid Leukaemia April 2014 Phase 2
    NCT00458848 Gruppo Italiano Malattie EMatologiche dell'Adulto Leukemia October 2004 Phase 2
    NCT00055874 III. Medizinische Klinik Mannheim|National Cancer Institute (NCI) Leukemia June 2002 Phase 3
    NCT00044304 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) Hypereosinophilic Syndrome August 22, 2002 Phase 2
    NCT00193349 SCRI Development Innovations, LLC|Novartis|Pharmacia and Upjohn Lung Cancer September 2002 Phase 2
    NCT00415857 M.D. Anderson Cancer Center|The Vaccine Company Leukemia December 2006 Phase 2
    NCT00006343 Novartis|National Cancer Institute (NCI) Leukemia June 2000 Phase 3
    NCT01271166 Novartis Pharmaceuticals|Novartis Advanced Colorectal Cancer October 2007 Phase 1
    NCT01114087 Assistance Publique - Hôpitaux de Paris Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumors October 2008
    NCT00015860 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Leukemia May 2001 Phase 1|Phase 2
    NCT00427999 Novartis Pharmaceuticals|Novartis Prostate Cancer February 2007 Phase 2
    NCT00769327 Gruppo Italiano Malattie EMatologiche dell'Adulto Leukemia February 2009 Phase 2
    NCT02326311 Azienda Ospedaliera Spedali Civili di Brescia Leukemia, Chronic Myeloid June 2015 Phase 3
    NCT00049569 National Cancer Institute (NCI) L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia January 2003
    NCT03170180 Samsung Medical Center Stomach Neoplasms March 1, 2017 Phase 2
    NCT02352558 Boston Biomedical, Inc Hematologic Malignancy May 2015 Phase 1
    NCT00036738 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Adult Acute Lymphoblastic Leukemia in Remission|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Relapsing Ch July 2001 Phase 2
    NCT02081378 Novartis Pharmaceuticals|Novartis Chronic Myelogenous Leukemia|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia April 25, 2014 Phase 1
    NCT01319981 M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc Leukemia March 2013 Phase 2
    NCT03214718 Assiut University Chronic Myeloid Leukemia Patients August 5, 2017
    NCT00327678 Assistance Publique - Hôpitaux de Paris|Group for Research in Adult Acute Lymphoblastic Leukemia Leukemia, Lymphocytic May 2006 Phase 3
    NCT00022737 National Cancer Institute (NCI) Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia October 2002 Phase 3
    NCT01312818 Masonic Cancer Center, University of Minnesota|Millennium Pharmaceuticals, Inc. Acute Lymphoblastic Leukemia June 2011 Phase 2
    NCT02013089 Sun Yat-sen University Gastrointestinal Cancers December 2013
    NCT02881086 Johann Wolfgang Goethe University Hospital Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma August 2016 Phase 3
    NCT01005914 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Leukemia June 2009 Phase 2
    NCT02638428 Samsung Medical Center|Ministry of health & welfare, Republic of Korea Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML December 2015 Phase 2
    NCT00973752 Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company Acute Lymphoblastic Leukemia August 2009 Phase 2
    NCT03023046 University of Washington|National Cancer Institute (NCI) Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|Philadelphia Chromosome Positive February 23, 2017 Phase 2
    NCT02538926 University of Washington|National Cancer Institute (NCI) B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma July 1, 2017 Phase 2
    NCT01771458 Institut Curie Reccurent/Metastatic Solid Tumor Disease October 2012 Phase 2
    NCT00882206 Masonic Cancer Center, University of Minnesota Leukemia|Lymphoma April 2009 Phase 2
    NCT00110058 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Leukemia February 2005 Phase 2
    NCT01085617 University College London Hospitals|National Cancer Institute (NCI) Leukemia|Mucositis|Oral Complications January 2010 Phase 3
    NCT01005758 Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) Leukemia January 2009 Phase 2
    NCT00061945 National Cancer Institute (NCI) Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymph June 2003 Phase 1|Phase 2
    NCT00002514 Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council Leukemia April 1993 Phase 3
    NCT00137111 St. Jude Children's Research Hospital|National Cancer Institute (NCI) Lymphoblastic Leukemia, Acute June 2000 Phase 3
    NCT03112603 Incyte Corporation Graft-versus-host Disease June 23, 2017 Phase 3
    NCT02894645 National University Hospital, Singapore Acute Lymphoblastic Leukemia (ALL) October 2008 Phase 4
    NCT02611492 Assistance Publique - Hôpitaux de Paris Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia April 2016 Phase 3
    NCT00476190 Dana-Farber Cancer Institute|Massachusetts General Hospital|Boston Children’s Hospital|NCIC Clinical Trials Group Acute Lymphoblastic Leukemia April 2007 Phase 2
    NCT00613171 Novartis Pharmaceuticals|Novartis Systemic Sclerosis, Scleroderma January 2008 Phase 2
    NCT01742299 Novartis Pharmaceuticals|Novartis GIST and CML March 26, 2013 Phase 4
    NCT00511303 University of Bologna|Novartis Chronic Myeloid Leukemia August 2000 Phase 2
    NCT01316458 Novartis Pharmaceuticals|Novartis Prostatic Neoplasm|Genital Neoplasms, Male|Neoplasms, Abdominal|Urogenital Neoplasms|Genital Diseases, Male|Prostatic Diseases|Antineoplastic Agents|Imatinib June 2003 Phase 2
    NCT02127372 Duke University Non-small Cell Lung Cancer November 2004 Phase 1|Phase 2
    NCT00511121 University of Bologna|Novartis|Schering-Plough Chronic Myeloid Leukemia April 2001 Phase 2
    NCT00135005 Novartis Pharmaceuticals|Novartis Gastrointestinal Stromal Tumors August 2005 Phase 1
    NCT00276926 University of Bologna|Novartis Hypereosinophilic Syndrome|Chronic Eosinophilic Leukemia (CEL)|Myeloproliferative Disorders March 2003 Phase 2
    NCT01468688 Novartis Pharmaceuticals|Novartis 3rd Line GIST April 20, 2012 Phase 1
    NCT00514488 University of Bologna|Novartis Chronic Myeloid Leukemia June 2004 Phase 3
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 1.6957 mL 8.4787 mL 16.9575 mL
    5 mM 0.3391 mL 1.6957 mL 3.3915 mL
    10 mM 0.1696 mL 0.8479 mL 1.6957 mL
    Cell Assay
    [4]

    Imatinib Mesylate is dissolved in DMSO and stored, and then diluted with appropriate media before use[4].

    Tested A549 cells are placed in 96-well flat-bottom plates at a density of 5×103 cells per well 24 h before the addition of the test compounds. The cells are incubated for 96 h with two different concentrations (10 and 100 nM) of PRI-2191 and concurrently with various concentrations of Imatinib mesylate (10, 100, 1000 and 10,000 ng/mL) and other cytostatic drugs (Docetaxel (DTX) or Idarubicin (ID) : 0.1, 1, 10, 100 ng/mL; Cisplatin (CIS): 1, 10, 100, 1000 ng/mL). The sulforhodamine B (SRB) assay is performed to evaluate the cytotoxic effect. As a result, IC50 is calculated for each separate experiment in Cheburator 0.4, Dmitry Nevozhay software[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4][5]

    Imatinib Mesylate is dissolved in DMSO and diluted in water (Mice)[4].
    Imatinib Mesylate (50 mg/kg) is dissolved in 0.5 mL of 20% DMSO (Rat)[5].

    Mice[4]
    NOD/SCID female mice, 12-16 weeks old, body weight of 20-25 g, are used. Mice are subcutaneously (s.c.) inoculated in the right flank of the abdomen with A549 tumor cells suspension (5×106 cells in 0.2 mL of Hank’s medium per mouse, Day 0) and then are randomized into groups receiving varied combinations of vitamin D analogs and chemotherapeutics. One out of two experimental protocols is applied in the respective experiments: 1. The treatment is started from Day 7 after inoculation of tumor cells (when tumors become palpable). Imatinib mesylate is administered intraperitoneally (i.p.) at a dose of 75 mg/kg/day, daily for 19 days (from Days 7-25). PRI-2191 is administered s.c. or by oral gavage at a dose of 2 μg/kg/day, 3 times a week (on Days 7, 12, 14, 16, 19, 21 and 23). 2. The treatment is started from Day 7 after inoculation of tumor cells (when tumors become palpable). Imatinib mesylate is administered intraperitoneally (i.p.) at a dose of 50 mg/kg/day, daily for 13 days (from Days 7-19). PRI-2191 and PRI-2205 are administered s.c. at doses of 1 or 10 μg/kg/day, respectively, 3 times a week (on Days 7, 10, 12, 14, 17, 19, 21, 24 and 26). At the end of the experiments, blood is collected under anesthesia; then, the mice are sacrificed.
    Rat[5]
    Male Lewis rats weighing 270 to 320 g are used in the experiments. Imatinib mesylate (50 mg/kg) is injected intraperitoneally in the Imatinib group (n=7), and 0.5 mL of 20% DMSO without Imatinib is administered in the vehicle group (n=7). The dose of 25 mg/kg is preliminarily tested, and it produces a little improvement in lung function without statistical significance. The dose of 50 mg/kg and intraperitoneal administration are adopted based on this result and past reports. The animals undergo left thoracotomy, and the left hilum is occluded with a small metallic clamp. The occlusion is performed 20 minutes after Imatinib or vehicle administration. During clamping, the tidal volume (TV) and respiratory rate (RR) are adjusted to 8 mL/kg and 80 breaths/min, respectively. After 90 minutes of ischemia, the clamp is removed and reperfusion is maintained for 120 minutes. During reperfusion, blood flow and ventilation are restored in the bilateral lung. In the sham group (n=6), the animals are heparinized, thoracotomized, and ventilated for 210 minutes. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    589.71

    Formula

    C₃₀H₃₅N₇O₄S

    CAS No.

    220127-57-1

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 49 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.90%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Imatinib Mesylate
    Cat. No.:
    HY-50946
    Quantity: